Skip to main content
PMC home page
Clinical and Diagnostic Laboratory Immunology logoLink to Clinical and Diagnostic Laboratory Immunology
. 1997 Nov;4(6):764–768. doi: 10.1128/cdli.4.6.764-768.1997

Gamma interferon prevents diabetes in the BB rat.

D O Sobel 1, J Newsome 1
PMCID: PMC170655  PMID: 9384304

Abstract

The BB rat model of human insulin-dependent diabetes mellitus (IDDM) spontaneously develops diabetes through an autoimmune process. Gamma interferon (IFN-gamma) is thought to play an important pathogenic role. This study examined if IFN-gamma administration can, paradoxically, prevent diabetes in BB rats. Diabetes-prone BB rats were initially injected intraperitoneally with murine recombinant IFN-gamma (rIFN-gamma) at doses of 0.5 x 10(4) to 40 x 10(4) U three times a week for 6 weeks beginning at 35 days of age. The effects of altering the duration of treatment (2 to 6 weeks) and the age at which injections were initiated (45 through 65 days) were also assessed. rIFN-gamma administration prevented the development of diabetes in a dose-dependent manner. The optimal treatment condition resulted in a 9.1% incidence of diabetes versus a 90% incidence in control rats. This diabetes-sparing effect was long lasting and continued to 7 months of age. A 4- to 6-week course resulted in maximal inhibition. Treatment initiated as late as 55 days of age, when insulitis is already present, was effective in preventing diabetes. Islet inflammation was dramatically lower in rIFN-gamma- versus saline-injected rats (P < 0.01). Total leukocyte count and subpopulations of peripheral mononuclear cells were unaltered by rIFN-gamma. In summary, rIFN-gamma paradoxically and potently prevents diabetes in BB rats in a dose-dependent fashion by inhibiting islet inflammation. This diabetes-sparing effect occurs even when injections are initiated after evidence of the diabetic process is already present.

Full Text

The Full Text of this article is available as a PDF (845.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown T. D., Koeller J., Beougher K., Golando J., Bonnem E. M., Spiegel R. J., Von Hoff D. D. A phase I clinical trial of recombinant DNA gamma interferon. J Clin Oncol. 1987 May;5(5):790–798. doi: 10.1200/JCO.1987.5.5.790. [DOI] [PubMed] [Google Scholar]
  2. Colle E., Guttmann R. D., Seemayer T. Spontaneous diabetes mellitus syndrome in the rat. I. Association with the major histocompatibility complex. J Exp Med. 1981 Oct 1;154(4):1237–1242. doi: 10.1084/jem.154.4.1237. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ely J. M., Greiner D. L., Lubaroff D. M., Fitch F. W. Characterization of monoclonal antibodies that define rat T cell alloantigens. J Immunol. 1983 Jun;130(6):2798–2803. [PubMed] [Google Scholar]
  4. Ewel C. H., Sobel D. O., Zeligs B. J., Bellanti J. A. Poly I:C accelerates development of diabetes mellitus in diabetes-prone BB rat. Diabetes. 1992 Aug;41(8):1016–1021. doi: 10.2337/diab.41.8.1016. [DOI] [PubMed] [Google Scholar]
  5. Foulis A. K., McGill M., Farquharson M. A. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man--macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol. 1991 Oct;165(2):97–103. doi: 10.1002/path.1711650203. [DOI] [PubMed] [Google Scholar]
  6. Greiner D. L., Mordes J. P., Handler E. S., Angelillo M., Nakamura N., Rossini A. A. Depletion of RT6.1+ T lymphocytes induces diabetes in resistant biobreeding/Worcester (BB/W) rats. J Exp Med. 1987 Aug 1;166(2):461–475. doi: 10.1084/jem.166.2.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Grönberg A., Ferm M. T., Ng J., Reynolds C. W., Ortaldo J. R. IFN-gamma treatment of K562 cells inhibits natural killer cell triggering and decreases the susceptibility to lysis by cytoplasmic granules from large granular lymphocytes. J Immunol. 1988 Jun 15;140(12):4397–4402. [PubMed] [Google Scholar]
  8. Holda J. H., Maier T., Claman H. N. Evidence that IFN-gamma is responsible for natural suppressor activity in GVHD spleen and normal bone marrow. Transplantation. 1988 Apr;45(4):772–777. doi: 10.1097/00007890-198804000-00021. [DOI] [PubMed] [Google Scholar]
  9. Jacob C. O., Holoshitz J., Van der Meide P., Strober S., McDevitt H. O. Heterogeneous effects of IFN-gamma in adjuvant arthritis. J Immunol. 1989 Mar 1;142(5):1500–1505. [PubMed] [Google Scholar]
  10. Lemmel E. M., Brackertz D., Franke M., Gaus W., Hartl P. W., Machalke K., Mielke H., Obert H. J., Peter H. H., Sieper J. Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma. Rheumatol Int. 1988;8(2):87–93. doi: 10.1007/BF00271840. [DOI] [PubMed] [Google Scholar]
  11. Lemmel E. M., Obert H. J., Hofschneider P. H. Low-dose gamma interferon in treatment of rheumatoid arthritis. Lancet. 1988 Mar 12;1(8585):598–598. doi: 10.1016/s0140-6736(88)91403-1. [DOI] [PubMed] [Google Scholar]
  12. Like A. A., Biron C. A., Weringer E. J., Byman K., Sroczynski E., Guberski D. L. Prevention of diabetes in BioBreeding/Worcester rats with monoclonal antibodies that recognize T lymphocytes or natural killer cells. J Exp Med. 1986 Oct 1;164(4):1145–1159. doi: 10.1084/jem.164.4.1145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mordes J. P., Desemone J., Rossini A. A. The BB rat. Diabetes Metab Rev. 1987 Jul;3(3):725–750. doi: 10.1002/dmr.5610030307. [DOI] [PubMed] [Google Scholar]
  14. Nakajima H., Takamori H., Hiyama Y., Tsukada W. The effect of treatment with interferon-gamma on type II collagen-induced arthritis. Clin Exp Immunol. 1990 Sep;81(3):441–445. doi: 10.1111/j.1365-2249.1990.tb05353.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Nakhooda A. F., Like A. A., Chappel C. I., Murray F. T., Marliss E. B. The spontaneously diabetic Wistar rat. Metabolic and morphologic studies. Diabetes. 1977 Feb;26(2):100–112. doi: 10.2337/diab.26.2.100. [DOI] [PubMed] [Google Scholar]
  16. Nicoletti F., Meroni P. L., Landolfo S., Gariglio M., Guzzardi S., Barcellini W., Lunetta M., Mughini L., Zanussi C. Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma. Lancet. 1990 Aug 4;336(8710):319–319. doi: 10.1016/0140-6736(90)91860-d. [DOI] [PubMed] [Google Scholar]
  17. Obert H. J., Brzoska J. F. Interferon gamma in der Therapie der chronischen Polyarthritis. Die Langzeitbehandlung in der Praxis. Arzneimittelforschung. 1989 Jul;39(7):819–822. [PubMed] [Google Scholar]
  18. Pukel C., Baquerizo H., Rabinovitch A. Destruction of rat islet cell monolayers by cytokines. Synergistic interactions of interferon-gamma, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes. 1988 Jan;37(1):133–136. doi: 10.2337/diab.37.1.133. [DOI] [PubMed] [Google Scholar]
  19. Sadelain M. W., Qin H. Y., Sumoski W., Parfrey N., Singh B., Rabinovitch A. Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. J Autoimmun. 1990 Dec;3(6):671–680. doi: 10.1016/s0896-8411(05)80034-4. [DOI] [PubMed] [Google Scholar]
  20. Sarvetnick N., Liggitt D., Pitts S. L., Hansen S. E., Stewart T. A. Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma. Cell. 1988 Mar 11;52(5):773–782. doi: 10.1016/0092-8674(88)90414-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Satoh J., Shintani S., Oya K., Tanaka S., Nobunaga T., Toyota T., Goto Y. Treatment with streptococcal preparation (OK-432) suppresses anti-islet autoimmunity and prevents diabetes in BB rats. Diabetes. 1988 Sep;37(9):1188–1194. doi: 10.2337/diab.37.9.1188. [DOI] [PubMed] [Google Scholar]
  22. Sobel D. O., Azumi N., Creswell K., Holterman D., Blair O. C., Bellanti J. A., Abbassi V., Hiserodt J. C. The role of NK cell activity in the pathogenesis of poly I:C accelerated and spontaneous diabetes in the diabetes prone BB rat. J Autoimmun. 1995 Dec;8(6):843–857. doi: 10.1016/s0896-8411(95)80021-2. [DOI] [PubMed] [Google Scholar]
  23. Tovo P. A., Cerutti F., Palomba E., Salomone C., Pugliese A. Evidence of circulating interferon-gamma in newly diagnosed diabetic children. Acta Paediatr Scand. 1984 Nov;73(6):785–788. doi: 10.1111/j.1651-2227.1984.tb17776.x. [DOI] [PubMed] [Google Scholar]
  24. Uchida A., Yanagawa E., Kokoschka E. M., Micksche M., Koren H. S. In vitro modulation of human natural killer cell activity by interferon: generation of adherent suppressor cells. Br J Cancer. 1984 Oct;50(4):483–492. doi: 10.1038/bjc.1984.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wahl S. M., Allen J. B., Ohura K., Chenoweth D. E., Hand A. R. IFN-gamma inhibits inflammatory cell recruitment and the evolution of bacterial cell wall-induced arthritis. J Immunol. 1991 Jan 1;146(1):95–100. [PubMed] [Google Scholar]
  26. Wallach D. Interferon-induced resistance to the killing by NK cells: a preferential effect of IFN-gamma. Cell Immunol. 1983 Feb 1;75(2):390–395. doi: 10.1016/0008-8749(83)90337-4. [DOI] [PubMed] [Google Scholar]
  27. Williams J. G., Jurkovich G. J., Hahnel G. B., Maier R. V. Macrophage priming by interferon gamma: a selective process with potentially harmful effects. J Leukoc Biol. 1992 Dec;52(6):579–584. doi: 10.1002/jlb.52.6.579. [DOI] [PubMed] [Google Scholar]
  28. Wilson C. A., Jacobs C., Baker P., Baskin D. G., Dower S., Lernmark A., Toivola B., Vertrees S., Wilson D. IL-1 beta modulation of spontaneous autoimmune diabetes and thyroiditis in the BB rat. J Immunol. 1990 May 15;144(10):3784–3788. [PubMed] [Google Scholar]
  29. Woda B. A., Biron C. A. Natural killer cell number and function in the spontaneously diabetic BB/W rat. J Immunol. 1986 Sep 15;137(6):1860–1866. [PubMed] [Google Scholar]
  30. Young H. A., Hardy K. J. Role of interferon-gamma in immune cell regulation. J Leukoc Biol. 1995 Oct;58(4):373–381. [PubMed] [Google Scholar]

Articles from Clinical and Diagnostic Laboratory Immunology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES